Epsilon M&A Deal Report - Irenat
Transaction Multiples for the Valuation of Private Companies
Alliance Pharma / Irenat
No EMAT :
63373
Announced Date :
14/01/2014
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Alliance Pharma
Target :
Irenat
Country :
Germany
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
Irenat is a sodium perchlorate monohydrate , marketed in Germany and is mainly used for diagnosing and treating hyperthyroidism . NB: Alliance has only acquired the rights to Irenat trademark. >...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
Rating :
*
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 34
| Date | Acquirer | Target | Country | Multiples | See details |
| 13/03/2014 | Vectura Group | Activaero | Germany | ** | 63201 |
| 16/12/2013 | Private Group led by DPE Deutsche Private Equity | Zellbios | Luxembourg | * | 63146 |
Source: Epsilon Research / EMAT
